Lu-AAZTA-NI-PSMA-093, a bivalent radiopharmaceutical agent designed for prostate cancer treatment, improves tumor targeting and retention. This is achieved by integrating a hypoxia-sensitive nitroimidazole (NI) group with a prostate-specific membrane antigen (PSMA) targeting moiety.
Molecular Weight:
1626.37
Formula:
C63H82LuN14O26
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
